Safety of carbonic anhydrase inhibitors

Expert Opinion on Drug Safety

Volumn 13, Issue 4, 2014, Pages 459-472

  Swenson, Erik R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acetazolamide; Carbonic anhydrase; Side effects; Sulfamate; Sulfonamide

Indexed keywords

ACETAZOLAMIDE; ACETIC ACID; BENDROFLUMETHIAZIDE; BICARBONATE; BRINZOLAMIDE; BUMETANIDE; CARBONATE DEHYDRATASE INHIBITOR; CELECOXIB; CHLOROTHIAZIDE; CHLORTALIDONE; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROFLUMETHIAZIDE; MAFENIDE; MEFRUSIDE; METHAZOLAMIDE; METOLAZONE; PIRETANIDE; SULFANILAMIDE; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; SULTIAME; THIAZIDE DIURETIC AGENT; TOPIRAMATE; TORASEMIDE; UNINDEXED DRUG; ZONISAMIDE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ALLERGIC REACTION; ANEMIA; ANOREXIA; APLASTIC ANEMIA; BICARBONATURIA; BLOOD DYSCRASIA; BLURRED VISION; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BRAIN DISEASE; CHOROID DETACHMENT; CONTACT DERMATITIS; CROSS REACTION; DEPRESSION; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; DYSPNEA; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; EYE IRRITATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERCALCIURIA; HYPEREMIA; HYPERGLYCEMIA; HYPOBICARBONATEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY FAILURE; LASSITUDE; LIBIDO DISORDER; LIVER CIRRHOSIS; LIVER DISEASE; LUNG DISEASE; MALAISE; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; MYOPIA; NAUSEA; NEPHROLITHIASIS; NONHUMAN; OPEN ANGLE GLAUCOMA; PARESTHESIA; RESPIRATORY FAILURE; REVIEW; SEVERE RENAL IMPAIRMENT; SUPPLEMENTATION; TERATOGENESIS; THROMBOCYTOPENIA; URINARY TRACT DISEASE; VISUAL DISORDER; WEIGHT REDUCTION;

ANIMALS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; HUMANS; SAFETY;

EID: 84899088472     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.897328     Document Type: Review

References (130)

1. Chegwidden WR, Carter ND, Edwards YN. The carbonic anhydrases: new horizons. EXS Birkhauser, Basel; 2000
2. Frost SC, McKenna R. Carbonic anhydrases: mechanism, regulation, links to disease, and industrial applications. Springer, Heidelberg; 2014
3. Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005-2013). Expert Opin Ther Pat 2013;23:681-91
4. McKenna R, Supuran CT. Carbonic anhydrase inhibitors drugs design. Carbonic anhyrases: mechanism, regulation, links to disease, and industrial applications. Springer, Heidelberg; 2014. p. 291-323
5. Carta F, Scozzafava A, Supuran CT. Sulfonamides: a patent review (2008-2012). Expert Opin Ther Pat 2012;22:747-58
6. Swenson ER. Carbonic anhydrase inhibitors and high altitude illnesses. In: Frost SC, McKenna R, editors, Carbonic anhydrase: mechanism, regulation, links to disease, and industrial applications. Springer, Heidelberg; 2014. p. 361-86
7. Smith DA, Jones RM. The sulfonamide groups as a structural alert: a distorted story. Curr Opin Drug Discov Devel 2008;11:72-9
8. Maren TH. Carbonic anhydrase: chemistry, physiology and inhibition. Physiol Rev 1967;47:595-781
9. Swenson ER. Respiratory and renal roles of carbonic anhydrase. In: Chegwidden WR, Carter ND, Edwards YN, editors, The carbonic anhydrases: new horizons. EXS Birkhauser, Basel; 2000. p. 281-341
10. Maren TH. Use of inhibitors in physiological studies of carbonic anhydrase. Am J Physiol 1977;2324:F291-7
11. Bennett CM, Brenner BM, Berline RW Micropuncture study of nephron function in the rhesus monkey. J Clin Invest 1968;47:203-16
12. Tucker BJ, Blantz RC. Effect of furosemide administration on glomerular and tubular dynamics in the rat. Kidney Int 1984;26:112-21
13. Berg JT, Ramanathan S, Gabrielli MG, Swenson ER. Carbonic anhydrase in mammalian vascular smooth muscle. J Histochem Cytochem 2004;52:1101-6
14. Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: mechanisms of action and effect on cardiovascular events. Curr Hypertens Rep 2013;15:514-21
15. Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother 2006;7:811-23
16. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30:230-40
17. Thone J, Leniger T, Splettstosser F, Wiemann M. Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. Epilepsy Res 2008;79:105-11
18. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Arch Ophthalmol 1977;95:1378-82
19. Vahedi K, Taupin P, Djomby R, et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: randomized placebo-controlled study. J Neurol 2002;249:206-11
20. Maren TH, Conroy CW, Wynns GC, Levy NS. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 1997;13(1):23-30
21. Heller I, Halevy J, Cohen S, Theodor E. Significant metabolic acidosis induced by acetazolamide. Not a rare complication. Arch Intern Med 1985;145:1815-17
22. Chapron DJ, Gomolin IH, Sweeney KR Acetazolamide blood concentrationsare excessive in the elderly; propensity for acidosis and relationship to renal function. J Clin Pharmacol 1989;29:348-53
23. Siklos P, Henderson RG. Severe acidosis from acetazolamide in a diabetic patient. Curr Med Res Opin 1979;6:284-6
24. Alper AB, Tomlin H, Sadhwani U, et al. Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase inhibition activity: a randomized controlled trial. Am J Ther 2006;13:229-35
25. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal salt diet. Clin Pharmacol Ther 2002;72:50-61
26. Whelton A, Lefkowith JL, West CR Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006;70:1495-502
27. Benson P, Yudd M, Sims D, et al. Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma. Clin Nephrol 2012;78:376-81
28. Welch BJ, Graybead D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate therapy. Am J Kidney Dis 2006;48:555-63
29. Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol 2009;68:655-61
30. Mizra NS, Alfirevic A, Jorgensen A, et al. Metabolic acidosis with topiramate and zonisamide: an assessment of it severity and predictors. Pharmacogenet Genomics 2011;21:297-302
31. Go T. Effect of antiepileptic drug polypharmacy on crystalluria. Pediatr Neurol 2005;32:113-15
32. Simpson DP. Effect of acetazolamide on citrate excretion in the dog. Am J Physiol 1964;206:883-6
33. Unwin RJ, Capasso G, Shirley DG. An overview of divalent cation and citrate handling by the kidney. Nephron Physiol 2004;98:15-20
34. Higashihara E, Nutahara K, Takeuchi T, et al. Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate. J Urol 1991;145:942-8
35. Wakabayashi Y. Hyperkalemia induced by a carbonic anhydrase inhibitor. Br J Ophthalmol 1991;75:176-7
36. Fulop M, Brazeau P. The phosphaturic effect of sodium bicarbonate and acetazolamide in the dog. J Clin Invest 1968;47:983-91
37. Krieger NS, Frick KK, Bushinsky DA. Mechanisms of acid induced bone loss. Curr Opin Nephrol Hypertens 2004;13:423-36
38. Swenson ER. Carbonic anhydrase inhibitors and ventilation: a complex interplay of stimulation and depression. Eur Respir J 1998;12:1242-7
39. Coudon WL, Block AJ. Acute respiratory failure precipitated by a carbonic anhydrase inhibitor. Chest 1976;69:112-13
40. Gonzalez JU, Scheuermann BW. Effect of acetazolamide on respiratory muscle fatigue in humans. Respir Physiol Neurobiol 2013;185:386-92
41. Kiwull-Schone HF, LI Y, Kiwull PJ, Teppema LJ. Methazolamide does not impair respiratory work performance in anesthetized rabbits. Am J Physiol 2009;297:R648-54
42. Parkkila S, Parkilla AK. Carbonic anhydrase in the alimentary tract. Scand J Gastroenterol 1996;31:305-17
43. Charney AN, Feldman GM. Systemic acid-base disorders and intestinal electrolyte transport. Am J Physiol 1984;247:G1-12
44. Arrigg CA, Epstein DL, Giovanni R Grant WM. The influence of supplemental sodium acetate on carbonic anhydrase inhibitor-induced side effects. Arch Ophthalmol 1981;99:1969-72
45. Plum JB, Plum F. The toxic effects of carbon dioxide and acetazolamide in hepatic encephalopathy. J Clin Invest 1960;39:1246-58
46. Warren KS, Schenker S. Drugs related to the exacerbation or amelioration of hepatic coma and their effects on ammonia toxicity. Clin Sci 1963;25:11-15
47. -, pH and the activity of carbonic anhydrase. Eur J Biochem 1985;152:381-6
48. Tannen RL, Ross BD. The impact of acetazolamide on renal ammoniagenesis and gluconeogenesis. J Lab Clin Med 1983;102:536-40
49. Kim JM, Ryu WS, Hwang YH, Kim JS. Aggravation of ataxia due to acetazolamide induced hyperammonaemia in episodic ataxia. J Neurol Neurosurg Psychiatry 2007;78:771-2
50. Das SN, Sadhu DP. Effect of acetazolamide on insulin sensitivity in dogs with alloxan diabetes. Indian J Physiol Pharmacol 1978;22:301-4
51. Dodgson SJ, Forster RE. Inhibition of CA V decreases glucose synthesis from pyruvate. Arch Biochem Biophys 1986;251:198-204
52. Dodgson SJ, Cherian K. Rat renal proximal tubular gluconeogenesis: possible involvement or non-mitochondrial carbonic anhydrase isozymes. Arch Biochem Biophys 1990;282:1-7
53. Konstantopoulos N, Molero JC, McGee SL, et al. Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo. Diabetes 2012;61:2146-54
54. Rames I, Kristufek V. Effect of different saluretics on carbohydrate metabolism and blood pressure behavior in diabetics. Dtsch Z Verdau Stoffwechselkr 1984;44:89-94
55. Grossman AJ, Batterman RC. Effects of acetazolamide (Diamox) upon blood sugar of normal and diabetic patients. Proc Soc Exp Biol Med 1956;93:255-6
56. Zaidi FH, Kinnear PE. Acetazolamide, alternate carbonic anhydrase inhibitors and hypoglycemic agents; comparing enzymic with diuresis induced metabolic acidosis following intraocular surgery in diabetes. Br J Ophthalmol 2004;88:714-15
57. Gabrilove JL, Alvarez AA, Soffer LJ. Effect of acetazolamide (Diamox) on thyroid function. J Appl Physiol 1958;13:491-2
58. Krieger DT, Moses A, Ziffer H, et al. Effect of acetazolamide on thyroid metabolism. Am J Physiol 1959;196:291-4
59. Chow SY, Kemp JW, Woodbury DM. Effects of acetazolamide on iodide transport, electrolyte distribution and activities of carbonic anhydrase, Na-K ATPase and HCO3 ATPase in mouse, rat and turtle thyroid glands. J Endocrinol 1983;97:167-74
60. Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 1976;16:309-27
61. Shulkin D, Olson BR, Levey GS. Thyrotoxic periodic paralysis in a Latin-American taking acetazolamide. Am J Med Sci 1989;297:337-8
62. Wiholm BE, Emanuelsson S. Drug-induced blood dyscrasias in a Swedish reporting system. Eur J Haematol Suppl 1996;60:42-6
63. Mogk LG, Cyrlin MN. Blood dyscrasias and carbonic anhydrase inhibitors. Ophthalmology 1988;95:768-71
64. Kodjikian L, Durant B, Burillon C, et al. Acetazolamide-induced thrombocytopenia. Arch Ophthalmol 2004;122:1543-4
65. Martin XD, Danese M. Dorzolamide-induced immune thrombocytopenia: as case report and literature review. J Glaucoma 2001;10:133-5
66. Campbell AR, Andress DL, Swenson ER. Identification and characterization of human neutrophil carbonic anhydrase. J Leukoc Biol 1994;55:343-8
67. Kawaai H, Seino H, Yamazaki S, Taki K. Changes in leukocyte migration during carbonic anhydrase activity inhibition. Burns 2009;35:397-404
68. Coakley RJ, Taggart C, Greene C, et al. Ambient pCO2 modulates intracellular pH, intracellular oxidant generation, and interleukin-8 secretion in human neutrophils. J Leukoc Biol 2002;71(4):603-10
69. Bryant BP. The roles of carbonic anhydrase in gustation, olfaction and chemical irritation. EXS 2000;90:365-74
70. Ferris KE, Clark RD, Coates EL. Topical inhibition of nasal carbonic anhydrase affects the CO2 detection threshold in rats. Chem Senses 2007;32:263-71
71. Kivela J, Parkkila S, Parklia AK, et al. Salivary carbonic anhydrase isoenzyme VI. J Physiol 1999;520:315-20
72. Chandrashekar J, Yartmolinsky D, von Bucholz L, et al. The taste of carbonation. Science 2009;326:443-5
73. Wang J, Ke T, Zhang X, et al. Effects of acetazolamide on cognitive performance during high-altitude exposure. Neurotoxicol Teratol 2013;35:28-33
74. Collier D, Swenson ER, Hedges AM, et al. Benzolamide improves oxygenation and reduces acute mountain sickness during a high altitude trek and has fewer side effects than acetazolamide. Pharmacol Res Perspect 2014; In press
75. Yang MT, Chien WL, Lu DH, et al. Acetazolamide impairs fear memory consolidation in rodents. Neuropharmacology 2013;67:412-18
76. Saito H, Ogaswwara K, Suzuki T, et al. Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity. Neurol Med Chir (Tokyo) 2011;51:479-83
77. Huang SY, McCullough RE, McCullough RG, et al. Usual clinical dose of acetazolamide does not alter cerebral blood flow velocity. Respir Physiol 1988;72:315-26
78. Grossman WM, Koeberle B. The dose-response relationship of acetazolamide on the cerebral blood flow in normal subjects. Cardiovasc Dis 2000;10:65-9
79. Maren TH, Ellison AC. The teratological effect of benzolamide, a new carbonic anhydrase. Johns Hopkins Med J 1972;130:116-23
80. Landauer W, Wakasugi N. Teratological studies with sulphonamides and their implications. J Embryol Exp Morphol 1968;20:261-84
81. Halladay DW, Layton WM. Forelimb deformity of offspring of rats given dichlorphenamide. Riv Patol Nevr Ment 1966;87:6-8
82. Bell SM, Schreiner CM, Resnick E, et al. Exacerbation of acetazolamide teratogenesis by amiloride and its analogs active against Na+/H+ exchangers and Na+ channels. Reprod Toxicol 1997;11:823-31
83. Ugen KE, Scott WJ. Reduction of uterine blood flow by phenylephrine, an alpha-adrenergic agonist, in the day 11 pregnant rat: relationship to potentiation of acetazolamide teratogenesis. Teratology 1987;36:133-41
84. Merlob P, Litwin A, Mor N. Possible association between acetazolamide administration during pregnancy and metabolic disorders in the newborn. Eur J Obstet Gynecol Reprod Biol 1990;35:85-8
85. Widengard I, Mandahl A, Tornquist P, Wistrand PJ. Colour vision and side-effects during treatment with methazolamide. Eye (Lond) 1995;9:130-5
86. Kwon SJ, Park DH, Shin JP. Bilateral transient mypopia, angle closure glaucoma, and choroidal detachment induced by methazolamide. Jpn J Ophthalmol 2012;56:515-17
87. Katz LJ, Simmons ST, Craven ER. Efficacy and safety of brinzolamide and dorzolamide in the intraocular pressure lowering in glaucoma and ocular hypertension. Curr Med Res Opin 2007;23:2971-83
88. Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open angle glaucoma and ocular hypertension. Drugs Aging 2003;20:919-47
89. Holdiness MR. Contact dermatitis to topical drugs for glaucoma. Am J Contact Dermat 2001;12:217-19
90. Servat JJ, Bernadino CR. Effects of common topical antiglaucoma medications on the ocular surface. Drugs Aging 2011;28:267-82
91. Teppema LJ, Balanos GM, Steinbeck CD, et al. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia. Am J Respir Crit Care Med 2007;175:277-81
92. Höhne C, Pickerodt PA, Francis RC, Swenson ER. Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition. Am J Physiol 2007;292:L178-84
93. Shimoda LA, Luke T, Sylvester JT, Swenson ER. Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition. Am J Physiol 2007;292:L1002-12
94. Pickerodt P, Swenson ER. Pulmonary vasodilation by acetazolamide during hypoxia: impact of methyl-group substitutions and administration route in conscious, spontaneously breathing dogs. J Appl Physiol 2014; In press
95. Pickkers P, Garcha RS, Schachter M, et al. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorthiazide. Hypertension 1999;33:1043-8
96. Pickkers P, Hughes AD, Russel FGM, et al. In vivo evidence of KCa channel opening properties of acetazolamide in the human vasculature. Br J Pharmacol 2001;132:443-50
97. Haustein M, Spoerl E, Boehm AG. The effect of acetazolamide on different ocular vascular beds. Graedfes Arch Clin Exp Ophthalmol 2013;251:1389-98
98. Horita Y, Yakabe K, Tadokoro M, et al. Renal circulatory effects of acetazolamide in patients with essential hypertension. Am J Hypertens 2006;19:282-5
99. Taki K, Oogushi K, Hirahara K, et al. Preferential acetazolamide-induced vasodilation based upon vessel size and organ. Angiology 2001;52:483-8
100. Aamand R, Dalsgaard T, Jensen FB, et al. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and vasodilation. Am J Physiol 2009;297:H2068-74
101. Chobanyan-Jürgens K, Schwarz A, Bohmer A, et al. Renal carbonic anhydrases are involved in the reabsorption of endogenous nitrite. Nitric Oxide 2012;26:126-31
102. Swenson ER. Carbonic anhydrase and the heart. Cardiologia 1997;42:453-62
103. Shimotsu Y, Hayashida K, Kume N, et al. Acetazolamide induced myocardial ischemia in patients with severe coronary artery disease. Ann Nucl Med 1998;12:21-7
104. Anderson CJ, Kaufman PL, Strum RJ. Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin. Am J Ophthalmol 1978;86:516-19
105. Rousseau P, Fuentevilla CA. Acetazolamide and salicylate interaction in the elderly. J Am Geriatr Soc 1993;41:868-9
106. Cowan RA, Haratnell GG, Lowdell CP, et al. Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function. Br Med J (Clin Res Ed) 1984;289:347-8
107. Hazouard E, Grimbert M, Jonville-Berra A, et al. Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid. J Fr Ophtalmol 1999;22:73-5
108. Lidell NE, Maren TH. CO2 retention as a basis for increased toxicity of salicylate with acetazolamide; avoidance of increased toxicity with benzolamide. J Pharmacol Exp Ther 1975;195:1-7
109. Sweeney KR, Chapron DJ, Brandt JL, et al. Toxic interaction between acetazolamide and salicylate; case reports and a pharmacokinetic explanation. Clin Phramacol Ther 1986;40:518-24
110. Sweeney KR, Chapron DJ, Anatal EJ, Kramer PA. Differential effects of flurbiprofen and aspirin on acetazolamide disposition in humans. Br J Clin Pharmacol 1989;27:866-9
111. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions. Drug Metab Dispos 1990;18:595-606
112. Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13(Suppl 1):S5-9
113. Lichter PR. Reducing side effects of carbonic anhydrase inhibitors. Ophthamology 1981;88:266-9
114. Lichter PR, Newman LP, Wheeler MS, Beall OP. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol 1978;85:495-502
115. Tilles SA. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J 2001;94:817-24
116. Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-reactivity? Am J Health Syst Pharm 2013;70:1483-94
117. Smith DA, Jones RM. The sulfonamide group as a structural alert: a distorted story? Curr Opin Drug Discov Devel 2008;11:72-9
118. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide non-antibiotics. N Engl J Med 2003;349:1628-35
119. Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmcogenomics 2010;11:879-84
120. Kelly TE, Hackett PH. Acetazolamide and sulfonamide allergy: a not so simple story. High Alt Med Biol 2010;11:319-23
121. Lee AG, Andreson R, Kardon RH, Wall M. Presumed "sulfa allergy" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross reactivity, myth or reality? Am J Ophthalmol 2004;138:114-18
122. Firoz EF, Firoz BF, Williams JF, Henning JS. Allergic contact dermatitis to mafenide acetate: a case series and review of the literature. J Drugs Dermatol 2007;6:825-8
123. Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008-2013). Expert Opin Ther Pat 2013;23:737-49
124. Cousin JL, Motais R. The role of carbonic anhydrase inhibitors ion anion permeability into ox red blood cells. J Physiol 1976;256:61-80
125. - exchanger, AE1. Mol Membr Biol 2004;21:423-33
126. Tamimura Y, Hiroaki Y, Fujiyoshi Y. Acetazolamide reversibly inhibits waster conduction by aquaporin-4. J Struct Biol 2009;166:16-21
127. Schellenberg M, Prokosch V, Thanos S. Regulation of retinal proteome by topical antiglaucomatous eye drops in an inherited glaucoma rat mode. PLoS One 2012;7:e33593
128. Lisk C, McCord J, Bose S, et al. Nrf2 activation: a potential strategy for the prevention of acute mountain sickness. Free Radic Biol Med 2013;63:264-73
129. Pickkers P, Hughes AD, Russel FG, et al. In vivo evidence for K(Ca) channel opening properties of acetazolamide in the human vasculature. Br J Pharmacol 2001;132:443-50
130. Temperini C, Innocenti A, Mastrolorenzo A, et al. Carbonic anhydrase inhibitors. Interaction of the anti-epileptic drug sulthiame with twelve mammalian isoforms. Bioorg Med Chem Lett 2007;17:4866-72